Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 14Ganglioneuroblastoma 3Glioblastoma 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia 1Gliosarcoma 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Temozolomide 53Bevacizumab 45Radiotherapy 28Radiosurgery 21Carboplatin 14Erlotinib Hydrochloride 11Radiation 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Etoposide 9Vorinostat 8Trastuzumab 8Irinotecan 8Sunitinib 7Sorafenib 7Radiotherapy, Intensity-Modulated 7Lomustine 7Lapatinib 7Capecitabine 7dabrafenib 6Ipilimumab 6Imatinib Mesylate 6Cyclophosphamide 6Sirolimus 5Hydroxyurea 5Everolimus 5Bortezomib 5temsirolimus 4cabozantinib 4binimetinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Brain Neoplasms × Isotretinoin × Clear all
NCT00528437 2021-07-08

Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

NYU Langone Health

Phase 2 Completed
46 enrolled 5 charts
CNS

Brain Neoplasms, Ependymoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡